Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action

NEXT STORY
Teleflex Interventional Urology Expands Portfolio with Introduction of the UroLift® Advanced Tissue Control (ATC)™ System
PREV STORY
TLC Reports Third Quarter 2020 Financial Results and Provides Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH)

Study Demonstrates that GM-CSF Neutralization with Lenzilumab in Combination with Chimeric Antigen Receptor T ...

author_avatar
NASDAQ Market News

Cellular Biomedicine Group to Provide Company Cancer Immunotherapy Pipeline Update and Facility Tour for Attendees of the Advanced Cell Therapy Summit in Shanghai

SHANGHAI, China and CUPERTINO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group ...

author_avatar
NASDAQ Market News

Global Ultrasound Device Market (2021 to 2027) – Focus on Diagnostic and Therapeutic Systems

author_avatar
NASDAQ Market News